{'fraction_non_alphanumeric': 0.03403811015400679, 'fraction_numerical': 0.01331245105716523, 'mean_word_length': 4.903235747303544, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The role of biomethylation in toxicity and carcinogenicity of arsenic: a research update.

Recent research of the metabolism and biological effects of arsenic has profoundly changed our understanding of the role of metabolism in modulation of toxicity and carcinogenicity of this metalloid. Historically, the enzymatic conversion of inorganic arsenic to mono- and dimethylated species has been considered a major mechanism for detoxification of inorganic arsenic. However, compelling experimental evidence obtained from several laboratories suggests that biomethylation, particularly the production of methylated metabolites that contain trivalent arsenic, is a process that activates arsenic as a toxin and a carcinogen. This article summarizes this evidence and provides new data on a) the toxicity of methylated trivalent arsenicals in mammalian cells, b) the effects of methylated trivalent arsenicals on gene transcription, and c) the mechanisms involved in arsenic methylation in animal and human tissues.

The metabolism of inorganic arsenic (iAs) in humans involves two types of chemical reactions, the reduction of pentavalent arsenicals to trivalency and the oxidative methylation of trivalent arsenicals to yield methylated pentavalent metabolites (1) (Figure 1). Glutathione (GSH) has been shown to reduce pentavalent arsenicals (arsenate iAs V ), methylarsonic acid (MAs V ), and dimethylarsinic acid (DMAs V ) in aqueous solutions (2,3). As V reductases may enzymatically reduce these arsenicals in mammalian tissues (4,5). Methylation of trivalent arsenicals [arsenite (iAs III ) and methylarsonous acid (MAs III )] is catalyzed by As III -methyltransferases that use S-adenosylmethionine (AdoMet) as the methyl group donor (6,7). Because MAs V and DMAs V are not toxic in acute lethality assays, methylation of iAs has long been considered a detoxification mechanism. However, methylated arsenicals that are chemically consistent with trivalent methylated metabolites, MAs III and dimethylarsinous acid (DMAs III ), have been shown to be more potent enzyme inhibitors and cytotoxins than either iAs V or iAs III (8). Diiodomethylarsine (MAs III I 2 ) and methylarsine oxide (MAs III O) are potent inhibitors of glutathione disulfide (GSSG) reductase (9), pyruvate dehydrogenase (10), and especially thioredoxin reductase (11). MAs III O and MAs III I 2 are also far more toxic than iAs III for various types of mammalian cells (12)(13)(14). DMAs III derivatives [iododimethylarsine (DMAs III I) and dimethylarsinousglutathione (DMAs III GS)] are at least as cytotoxic as iAs III for most cell types examined.
Notably, exposures to low concentrations of either MAs III O or DMAs III I induce cell proliferation and production of growthpromoting cytokines in normal human keratinocytes (NHEK) (15). Unlike iAs III and iAs V , MAs III O and DMAs III I react directly with DNA, nicking naked DNA in vitro and damaging nuclear DNA in intact human leukocytes (16). Evidence for the formation of methylated trivalent arsenicals in the course of the metabolism of iAs in humans has been obtained using optimized analytical techniques (17,18). MAs III and DMAs III have been detected in urine of individuals chronically exposed to iAs in drinking water (5,(18)(19)(20) and in cultured human hepatic cells exposed to various concentrations of iAs III (18). Studies are currently under way in several laboratories to elucidate the role of methylated trivalent metabolites in the systemic toxicity and carcinogenicity of iAs. This report summarizes some recent work linking the metabolism of arsenic to its biological effects.

Toxicity of Methylated Trivalent Arsenicals in Mammalian Cells
Cytotoxic effects of trivalent and pentavalent arsenicals have previously been examined in several cell types, including primary human hepatocytes, primary human bronchial epithelial cells (HBEC), NHEK), SV-40-immortalized human bladder epithelial (UROtsa) cells, HeLa cells (12,13), and Chang liver cells (14). Pentavalent arsenicals were significantly less cytotoxic than their trivalent counterparts (12)(13)(14). Among trivalent arsenicals, MAs III O and MAs III I 2 were the most cytotoxic species, followed by DMAs III I, DMAs III GS, and iAs III . We have recently examined cytotoxicity of arsenicals in several other mammalian cell types, including human hepatocellular carcinoma (HepG2) cells, human bladder transient carcinoma (T24) cells, human acute promyelocytic leukemia (NB4) cells, human monoblastoid (U937) cells, human osteosarcoma (HOS) cells, human neuroblastoma (SK-N-SH) cells, mouse 3T3 adipocytes, primary guinea pig hepatocytes, and Chinese hamster lung (V79-4) cells (Table 1). Regardless of the cell type, trivalent monomethylated arsenicals, MAs III O and MAs III I 2 , were the most potent cytotoxins, with LC 50 values ranging from 0.4 to 5.5 µM. DMAs III derivatives were as cytotoxic as MAs III species and more cytotoxic than iAs III in most cell types.
The thiazolyl blue (MTT) assay that monitors the activity of mitochondrial dehydrogenases in viable cells has been used to examine cytotoxicity of arsenicals in all these cell types. The neutral red assay that measures the uptake of the die by viable cells has also been used in some experiments. Because the cell viability values determined by the neutral red assay were lower that those obtained by the MTT assay (12,15), it is possible that the latter assay underestimates cytotoxic effects of arsenicals in cultured cells. Figure 2 shows an example of the concentration-dependent effects of trivalent arsenicals on cell viability in human leukemia NB4 and U937 cell lines. Increased cell viability values found after 24-hr exposures to low concentrations of arsenicals were associated with increased cell proliferation rates. The induction of cell proliferation by low concentrations of trivalent arsenicals has previously been reported in several cell types [e.g., NHEK (15)]. Notably, among cell types examined, NB4 cells were most sensitive to cytotoxic effects of trivalent arsenicals.
As shown in Table 1, there was no apparent correlation between the capacity of cells to methylate iAs and their sensitivity to the cytotoxic effects of trivalent arsenicals, indicating that the capacity to methylate has little to do with the resistance of cells to acute toxicity of As III . In some cases, iAs III was more toxic in cells with a high methylation capacity (e.g., rat hepatocytes) than in cells that do not methylate this arsenical (e.g., guinea pig hepatocytes). Consequently, mechanisms other than methylation (e.g., transport of arsenicals across the cell membrane or protein binding) may play a critical role in the detoxification of trivalent arsenicals under acute exposure conditions. These results suggest that production and accumulation of MAs III and/or DMAs III , the most cytotoxic species among biologically relevant arsenicals, may be directly linked to adverse effects associated with in vivo exposures to iAs. We have previously shown that HepG2 cells exposed to iAs III produced both MAs III and DMAs III . In addition, both MAs III and DMAs III synthesized in HepG2 cells were released into culture medium (18). Hence, MAs III and DMAs III may be translocated from methylating cells to tissues and cells that cannot methylate iAs. Notably, production of MAs III and DMAs III by HepG2 cells increased with increasing concentrations of iAs III in the culture. Similarly, epidemiologic studies have shown that urinary levels of MAs III and DMAs III in individuals exposed to iAs in drinking water are positively correlated with exposure levels (5,18). These results suggest that individuals exposed to higher levels of iAs may be at greater risk associated with the production of these toxic methylated metabolites.

Effects of Methylated Trivalent Arsenicals on Gene Transcription
Various hypotheses have been proposed to explain the carcinogenicity of iAs (28). Nevertheless, molecular mechanisms by which this arsenical induces cancer are still poorly understood. Results of previous studies indicated that iAs does not act through classic genotoxic and mutagenic mechanisms, but rather may be a tumor promoter that modifies signal transduction pathways involved in cell growth and proliferation (29). iAs III has been shown to modulate expression and/or DNAbinding activities of several key transcription factors, including nuclear factor kappa B (30), tumor suppressor 53 (p53) (31), and activating protein-1 (AP-1) (32-34). Mechanisms of AP-1 activation by iAs III include stimulation of the mitogen-activated protein kinase (MAPK) cascade with a consequent increase in the expression and/or phosphorylation of the two major AP-1 constituents, c-Jun and c-Fos (29). The modulation of AP-1-dependent gene transcription by iAs III may contribute to the induction of cell proliferation in cultured cells exposed to this arsenical. However, there are no data on the effects of methylated trivalent arsenicals on AP-1 composition and DNA-binding activity.
Recently, we have examined c-Jun and c-Fos expression and AP-1 DNA-binding Metals Toxicity • Sty 'blo et al.  Abbreviations: ND, not determined. a LC 50 is defined as the concentration of an arsenical that resulted in a 50% decrease in cell viability over a 24-hr incubation period. The MTT assay was used to examine cell viability in all cell types. b Methylation rates were determined in cultures exposed to 0.05 or 0.1 µM iAs III for 24 or 48 hr. c Methylation activity not detected. activity in several human cell lines, including UROtsa, T24, HepG2, and primary human hepatocytes exposed to trivalent or pentavalent inorganic or methylated arsenicals. Short-time exposures to trivalent, but not to pentavalent, arsenicals increased AP-1 DNAbinding activity in all these cell types. Most profound effects were found in UROtsa and T24 cells. In these cell lines, exposures to MAs III O or DMAs III I significantly increased the levels of nuclear phospho-c-Jun (p-c-Jun) but had no effects on either c-Jun or c-Fos levels (35). Importantly, MAs III O and DMAs III I were considerably more potent inducers of c-Jun phosphorylation and AP-1 activation than was iAs III . Neither iAs V nor methylated pentavalent arsenicals, MAs V or DMAs V , modified c-Jun phosphorylation. Figure 3 shows nuclear levels of p-c-Jun in UROtsa cells exposed for 1 hr to iAs III , MAs III O, or DMAs III I (0.5, 1, or 5 µM). MAs III O was the most potent inducer of p-c-Jun, followed by DMAs III I. In contrast, exposures to iAs III suppressed p-c-Jun levels in this cell line. The AP-1 DNA-binding activity was induced in UROtsa cells exposed to as little as 0.1 µM MAs III O (35), a concentration that is well below the LC 50 value for these cells ( Table 1). The potencies of MAs III O and DMAs III I to stimulate the AP-1-dependent gene transcription have further been demonstrated using UROtsa and T24 cells transiently transfected with an AP-1-dependent promoter-reporter construct (35). Somewhat different AP-1 activation patterns were observed in primary human hepatocytes ( Figure 4). Among trivalent arsenicals examined, MAs III O was the most potent inducer of c-Jun phosphorylation in these cells. However, only a weak induction of p-c-Jun was observed in human hepatocytes exposed to iAs III or DMAs III I. A significant induction of the AP-1 DNA-binding activity was detected by the electrophoretic mobility shift assay (EMSA) only in cells exposed to 5 µM MAs III O ( Figure 5). Under these exposure conditions, p-c-Jun, but not c-Fos, was the major constituent of the AP-1 DNA-binding complex. Based on these results, the AP-1 DNA-binding activity appears to be less sensitive to induction by trivalent arsenicals in primary human hepatocytes than in either UROtsa or T24 cell lines that are derived from human urinary bladder. Accordingly, trivalent arsenicals, particularly MAs III , are likely to induce the AP-1-dependent gene transcription in human bladder to a greater extent than in the liver. Notably, both hepatic and urinary bladder cancers have been associated with chronic exposures to iAs in drinking water. However, the incidence of bladder cancer exceeds that of hepatic cancer (36)(37)(38). Thus, trivalent methylated arsenicals that are chemically consistent with trivalent methylated metabolites of iAs are more potent than iAs, inducing the DNA-binding activity of AP-1, a key transcription factor that is involved in regulation of cell proliferation and death (29).

Mechanism of iAs Methylation
The enzymatic reactions involved in the reduction and methylation of arsenicals have Environmental Health Perspectives • VOLUME 110 | SUPPLEMENT Figure 3. Immunoblot analysis of p-c-Jun in nuclear protein extracts from UROtsa cells exposed to iAs III , MAs III O, or DMAs III I for 1 hr and from control (untreated) cells. Nuclear proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electroblotted on polyvinyl difluoride membranes. Membranes were blocked with 5% nonfat milk, washed, and probed with a mouse monoclonal antibody specific for p-c-Jun (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Blots were visualized by an enhanced chemiluminescence technology and quantified using a digital imaging system. Immunoblot images (A) and results of the quantitative analysis of these images (B) are shown. been studied in several laboratories using fractionated tissues, intact cells, and purified enzymes (8). Distinct As V reductases have been shown to catalyze reduction of iAs V to iAs III and of MAs V to MAs III (4,39). Both these enzymes require thiols (e.g., GSH) for reducing activity. The MAs V reductase (K m = 2.6 mM) has recently been identified as GSH-S-transferase omega (40). Methyltransferases that catalyze methylation of iAs III and MAs III have also been identified. A rabbit liver enzyme that converts iAs III to MAs and MAs III O to DMAs has been purified and partially characterized (6). This cytosolic protein has a molecular weight of about 60 kDa and requires both AdoMet and a thiol for activity. Consistent with the metabolic scheme in Figure 1, the purified enzyme has a greater affinity for MAs III than for MAs V . A novel As III methyltransferase (M r = 41 kDa) has recently been purified by Lin and co-workers (7) from rat liver. This enzyme methylates iAs III in a two-step reaction, in which MAs is an intermediate and DMAs is the final product. The two-step kinetics of this reaction is consistent with kinetic patterns of iAs III methylation reported in in vitro studies using tissue extracts (41,42). AdoMet is the essential methyl group donor for both methylation steps ( Table 2). MAs III O is also a substrate for this enzyme in a methylation reaction yielding DMAs. A kinetic analysis of this reaction showed a low K m of 250 nM MAs III O. Thus, this enzyme can effectively methylate at very low concentrations of MAs III in tissues. However, high concentrations of MAs III O (≥5 µM) inhibit DMAs synthesis. The rat As III methyltransferase requires a dithiol for its activity. Dithiothreitol (DTT) has been used as an enzyme co-factor in in vitro assays with purified rat As III methyltransferase. Protein and cDNA sequences for the rat As III methyltransferase have been obtained. Sequence analyses have revealed a high degree of homology with a putative human methyltransferase CYT19, indicating that CYT19 is the human As III methyltransferase. Using reverse-transcription polymerase chain reaction, mRNA for As III methyltransferase has been detected in rat tissues (liver, heart, lung, kidney, adrenal, bladder, and brain) and also in human hepatoma (HepG2) cells that are known to methylate iAs III (18). In contrast, mRNA for this enzyme has not been found in UROtsa cells, human urinary bladder cells that do not produce methylated metabolites when exposed to iAs III in culture (12,13).
Based on results of the in vitro studies, the presence of a dithiol is an essential requirement for the rat As III methyltransferase activity. Thioredoxin (TRx), a small (12 kDa) protein with a pair of redox-active cysteine residues (44), is a likely candidate for the role of a cofactor for this enzyme in mammalian cells. In fact, TRx and DTT are equally effective in supporting the in vitro As III methyltransferase activity (43). The main function of TRx in cells is the reduction of disulfide bonds in molecules of various proteins, including enzymes, cellular receptors, and transcription factors. During this reaction, the redox-active sulfhydryl groups in TRx molecule are oxidized to form a disulfide (45). The oxidized TRx is then reactivated in an NADPH-dependent reaction catalyzed by TRx-reductase (TR) (44).
The mechanism of interactions between TRx and As III methyltransferase has not been examined. It is likely that TRx is involved in the reduction of the pentavalent intermediate, MAs V . TRx may directly reduce MAs V to MAs III before the second methylation step. It may also be a donor of electrons for reduction (reactivation) of redox-active cysteinyl residues of the As III methyltransferase that are responsible for MAs V reduction. Alternatively, TRx may reduce other cysteinyl residues that are required for the catalytically active conformation of the enzyme. Notably, interactions between TRx and As III methyltransferase provide a basis for a hypothetical mechanism that may play an important role in the regulation of this enzyme ( Figure 6). It has been shown that MAs III derivatives [MAs III O or MAs III I 2 ] are potent inhibitors of TR (11), the enzyme responsible for TRx reactivation. In cell cultures exposed to iAs III , inhibition of TR activity correlates with accumulation of MAs in cells (46). These data suggest that MAs III , the intermediate formed in the course iAs methylation, is responsible for inhibition of TR activity. The inhibition of TR by MAs III may result in a decreased availability of the active (reduced) form of TRx in cells, preventing further reduction of MAs V to MAs III . This hypothetical regulatory mechanism would retard the formation of MAs III when the concentrations of this toxic intermediate in cells reached low micromolar values.

Conclusions
The results of previous studies and new experimental data presented here suggest that exposures to methylated trivalent arsenicals are associated with a variety of adverse effects that have a profound impact on cell viability or proliferation. The known effects include a) inhibition of several key enzymes, b) damage to DNA structure, and c) activation of AP-1-dependent gene transcription. Notably, trivalent methylated arsenicals, MAs III and/or DMAs III derivatives, are more potent than iAs III in producing these effects. These findings are consistent with the concept of biomethyla-770 VOLUME 110 | SUPPLEMENT 5 | OCTOBER 2002 • Environmental Health Perspectives Metals Toxicity • Sty 'blo et al.  Figure 6. Hypothetical mechanism of the methylation of iAs by As III methyltransferase: the role of Trx and TR. As V -R, As V reductase; As III -MT, As III methyltransferase.